公开(公告)号：US20240285613A1

公开(公告)日：2024-08-29

申请号：US18573362

申请日：2022-06-23

申请人： LDN Pharma Limited

发明人： Wai Liu ,  Ian Thompson ,  Francis Hood

IPC分类号： A61K31/485 ,  A61K31/00 ,  A61K31/01 ,  A61K31/015 ,  A61K31/045 ,  A61K31/08 ,  A61K31/133 ,  A61K31/135 ,  A61K31/137 ,  A61K31/164 ,  A61K31/165 ,  A61K31/232 ,  A61K31/343 ,  A61K31/352 ,  A61K31/353 ,  A61K31/357 ,  A61K31/366 ,  A61K31/4045 ,  A61K31/42 ,  A61K31/454 ,  A61K31/48 ,  A61K31/575 ,  A61K31/593 ,  A61K31/675 ,  A61K31/7048 ,  A61K45/06

CPC分类号： A61K31/485 ,  A61K31/01 ,  A61K31/015 ,  A61K31/045 ,  A61K31/08 ,  A61K31/133 ,  A61K31/135 ,  A61K31/137 ,  A61K31/164 ,  A61K31/165 ,  A61K31/232 ,  A61K31/343 ,  A61K31/352 ,  A61K31/353 ,  A61K31/357 ,  A61K31/366 ,  A61K31/4045 ,  A61K31/42 ,  A61K31/454 ,  A61K31/48 ,  A61K31/575 ,  A61K31/593 ,  A61K31/658 ,  A61K31/675 ,  A61K31/7048 ,  A61K45/06

摘要： A pharmaceutical composition comprising naltrexone or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine, for use in the treatment of an autoimmune disease within a subject, wherein a therapeutically effective amount of the naltrexone or metabolite thereof or analogue of either is to be administered to the subject in a first treatment phase, wherein after the first treatment phase the subject is to be administered a therapeutically effective amount of a cannabinoid, flavonoid or terpene in a second treatment phase, and wherein an agonist of a 5-hydroxytryptamine (5-HT) receptor is to be administered to the subject either simultaneously, sequentially or separately with the naltrexone, the metabolite or analogue.

公开(公告)号：US20240238186A1

公开(公告)日：2024-07-18

申请号：US18557661

申请日：2022-04-29

申请人： CarboCode S.A.

发明人： Bruce McConnell ,  Cornelia Pyko ,  Feryel Adam

IPC分类号： A61K8/68 ,  A61K31/164 ,  A61K31/7028 ,  A61Q17/00 ,  A61Q19/00 ,  A61Q19/08

CPC分类号： A61K8/68 ,  A61K31/164 ,  A61K31/7028 ,  A61Q17/00 ,  A61Q19/007 ,  A61Q19/08

摘要： The present invention relates to a topical composition comprising one or more compounds of formula (I), wherein X is hydrogen or a glycosyl moiety, the carbon-carbon bond noted is a double or a single bond, R1 is an alkyl chain having 10-20 carbon atoms, R2 is hydrogen or a substituted or unsubstituted acyl having 16-34 carbon atoms, R3 is hydrogen when the carbon-carbon bond noted is a double or a single bond, and R3 is —OH when the carbon-carbon bond noted is a single bond, R4 is hydrogen when the carbon-carbon bond noted is a double or a single bond, and R4 is hydrogen or —OH when the carbon-carbon bond noted is a double bond, said composition is characterized in that at least one of the one or more compounds of formula (I) has a lactosyl moiety or a glucosyl moiety in the position X.

公开(公告)号：US20240207205A1

公开(公告)日：2024-06-27

申请号：US18541626

申请日：2023-12-15

申请人： ELEONOR ,  TILMAN

发明人： Cristina LOIRA-PASTORIZA ,  Fabian PRIEM ,  Yvan DIERCKXSENS

IPC分类号： A61K31/164 ,  A61K9/14 ,  B29B7/34 ,  B29B7/82 ,  B29C48/00 ,  B29C48/88 ,  B29B9/12 ,  B29K77/00

CPC分类号： A61K31/164 ,  A61K9/145 ,  A61K9/146 ,  B29B7/34 ,  B29B7/82 ,  B29C48/022 ,  B29C48/911 ,  B29B9/12 ,  B29K2077/00

摘要： Compositions in the form of a thermoformed extrudate in any suitable form allowing administration to an animal or a human being, comprising at least one natural or synthetic N-alkylamide as active substance and at least one support of natural origin chosen from the group consisting of amino acids, peptides, polypeptides, proteins, saccharides, lipids, their derivatives and their mixtures. And methods of forming such thermoformed extrudates.

公开(公告)号：US12016835B2

公开(公告)日：2024-06-25

申请号：US17990329

申请日：2022-11-18

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Adam D. Hughes ,  Erik Fenster ,  Melissa Fleury ,  Roland Gendron ,  Edmund J. Moran

IPC分类号： A61K31/197 ,  A61K31/24 ,  A61K31/27 ,  A61K31/365 ,  A61K45/06 ,  C07C231/02 ,  C07C233/56 ,  C07C243/26 ,  C07C243/28 ,  C07C243/30 ,  C07C271/22 ,  C07D207/263 ,  C07D317/40 ,  C07D319/06 ,  A61K31/16 ,  A61K31/164 ,  A61K31/165 ,  A61K31/166 ,  A61K31/167

CPC分类号： A61K31/197 ,  A61K31/24 ,  A61K31/27 ,  A61K31/365 ,  A61K45/06 ,  C07C231/02 ,  C07C233/56 ,  C07C243/26 ,  C07C243/28 ,  C07C243/30 ,  C07C271/22 ,  C07D207/263 ,  C07D317/40 ,  C07D319/06 ,  A61K31/16 ,  A61K31/164 ,  A61K31/165 ,  A61K31/166 ,  A61K31/167

摘要： In one aspect, the invention relates to compounds having the formula:






where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

公开(公告)号：US11951208B1

公开(公告)日：2024-04-09

申请号：US18120432

申请日：2023-03-13

申请人： The Future Happens Everyday Inc.

发明人： Joseph Librizzi ,  Celeste Lee ,  Bryan Taylor ,  Lorrie King

IPC分类号： A61K9/107 ,  A61K31/164 ,  A61K36/899 ,  A61K47/10 ,  A61K47/14

CPC分类号： A61K9/107 ,  A61K31/164 ,  A61K36/899 ,  A61K47/10 ,  A61K47/14

摘要： Provided are low impact methods of creating concentrated water-in-oil and oil-in-water nanosized emulsions, effective therapeutic carriers for skin aging preparations. To achieve optimum multifunctional activity, ceramide and plant-based ceramides are selected to naturally mimic epidermal composition; and are made into evenly dispersed, small droplet, high-absorption skincare treatment emulsions. The water-in-oil emulsion is a highly stable, low-water ratio concentrate, of particular benefit to dry and aging skin types. The oil-in-water lipophilic emulsion maximizes lipid and nutrient release into the epidermis (stratum basale to stratum corneum). Lipophilic compositions are non-irritating and highly absorbable, resulting in superior skin health; specifically skin barrier keratinocyte, lipid and hydration improvements and aesthetic improvements, including skin smoothness and wrinkle reduction, while decreasing potential dermatitis and similar. Oil-in-water emulsions are achieved using a novel low-energy, low-cost flip phase methodology, in contrast to hot-stage high pressure homogenization techniques which yield inconsistent droplet sizes and are subject to oxidation.

公开(公告)号：US20240099998A1

公开(公告)日：2024-03-28

申请号：US18269973

申请日：2022-01-13

申请人： Dignify Therapeutics, LLC

发明人： Karl Bruce THOR ,  Lesley MARSON

IPC分类号： A61K31/165 ,  A61K9/00 ,  A61K31/164 ,  A61P1/10

CPC分类号： A61K31/165 ,  A61K9/0031 ,  A61K31/164 ,  A61P1/10

摘要： Methods, pharmaceutical formulations, and kits are provided for using Transient Receptor Potential Vanilloid 1 (TRPV1) agonists to increase rectal pressure and induce defecation in mammals.

公开(公告)号：US11931326B2

公开(公告)日：2024-03-19

申请号：US17861054

申请日：2022-07-08

申请人： DIET SHIELD LTD

发明人： Andrew Kitchner ,  Denis Carr

IPC分类号： A01N37/00 ,  A01N25/00 ,  A01N37/12 ,  A01N37/44 ,  A61K9/00 ,  A61K31/16 ,  A61K31/164 ,  A61K31/165 ,  A61K31/215 ,  A61K31/24 ,  A61K47/10 ,  A61K47/44 ,  A61P3/04 ,  A61P25/34

CPC分类号： A61K31/164 ,  A61K9/0014 ,  A61K31/16 ,  A61K31/165 ,  A61K47/10 ,  A61K47/44 ,  A61P3/04 ,  A61P25/34

摘要： Provided are compositions and methods comprising a sanshool for the treatment of obesity as part of a controlled diet regime in an individual. Also provided are compositions and methods comprising a sanshool for treatment of a smoking or vaping addiction. Suitably the compositions are applied topically to the lips of the individual in response to a habitual urge to consume food, smoke or vape as required.

公开(公告)号：US11899025B2

公开(公告)日：2024-02-13

申请号：US16982494

申请日：2019-03-21

申请人： KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

发明人： Jae-Sung Bae ,  Hee Kyung Jin ,  Ju Youn Lee ,  Seung Hoon Han

IPC分类号： G01N33/68 ,  G01N33/50 ,  G01N33/573 ,  A61K31/164

CPC分类号： G01N33/6896 ,  A61K31/164 ,  G01N33/5008 ,  G01N33/573 ,  G01N2333/90241 ,  G01N2440/10

摘要： The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising a COX2 acetylating agent as an active ingredient and, more particularly, to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising, as an active ingredient, a COX2 acetylating agent which exhibits an effect of inhibiting the deposition of amyloid-β in brain neurons, reducing excessive neuroinflammatory responses, and increasing the phagocytosis of amyloid-β in microglial cells. The pharmaceutical composition for preventing or treating neurodegenerative diseases comprising the COX2 acetylating agent as an active ingredient has the effects of alleviating neuroinflammation by promoting COX2 acetylation in neurons and secreting specialized pro-resolving mediators (SPMs) and thus, can be very useful in the development of a preventive or therapeutic agent for neurodegenerative diseases.

公开(公告)号：US20230364029A1

公开(公告)日：2023-11-16

申请号：US18218575

申请日：2023-07-05

申请人： PTC THERAPEUTICS, INC.

发明人： Paul MOLLARD ,  Peter GIANNOUSIS ,  Shazad SUCHIT ,  Mahmoud MIRMEHRABI ,  Christopher R. CORNELL ,  Kieron E. WESSON

IPC分类号： A61K31/122 ,  C07C215/30 ,  C07C215/08 ,  C07C235/78 ,  C07C215/28 ,  A61K31/164 ,  C07C231/12 ,  C07B57/00

CPC分类号： A61K31/122 ,  A61K31/164 ,  C07B57/00 ,  C07C215/08 ,  C07C215/28 ,  C07C215/30 ,  C07C231/12 ,  C07C235/78 ,  C07B2200/13 ,  C07C2601/16

摘要： Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.

公开(公告)号：US11779446B2

公开(公告)日：2023-10-10

申请号：US16196872

申请日：2018-11-20

申请人： 3M INNOVATIVE PROPERTIES COMPANY

发明人： Katie F. Wlaschin ,  Amanda C. Engler ,  Hannah C. Cohen ,  Yizhong Wang ,  Tao Gong ,  Tiffany T. Ton ,  Joel D. Oxman ,  Jie Yang ,  Richard P. Rusin

IPC分类号： A61C19/06 ,  A61P1/02 ,  A61K36/00 ,  A61Q11/00 ,  A61K9/12 ,  A61K8/25 ,  A61K8/41 ,  A61K8/73 ,  A61K8/92 ,  A61K47/12 ,  A61K9/107 ,  A61K47/26 ,  A61K8/81 ,  A61K8/06 ,  A61K9/00 ,  A61K47/10 ,  A61K8/37 ,  A61K36/185 ,  A61K47/36 ,  A61K47/44 ,  A61K36/28 ,  A61K36/63 ,  A61K31/025 ,  A61K31/075 ,  A61K31/164 ,  A61K31/198 ,  A61K31/205 ,  A61K31/355 ,  A61K31/714 ,  A61K31/728 ,  A61K36/48 ,  A61K36/52 ,  A61K36/736 ,  A61K36/752 ,  A61K36/81

CPC分类号： A61C19/063 ,  A61K8/062 ,  A61K8/25 ,  A61K8/375 ,  A61K8/41 ,  A61K8/73 ,  A61K8/731 ,  A61K8/732 ,  A61K8/737 ,  A61K8/8147 ,  A61K8/8176 ,  A61K8/922 ,  A61K9/006 ,  A61K9/0053 ,  A61K9/107 ,  A61K9/12 ,  A61K31/025 ,  A61K31/075 ,  A61K31/164 ,  A61K31/198 ,  A61K31/205 ,  A61K31/355 ,  A61K31/714 ,  A61K31/728 ,  A61K36/00 ,  A61K36/185 ,  A61K36/28 ,  A61K36/48 ,  A61K36/52 ,  A61K36/63 ,  A61K36/736 ,  A61K36/752 ,  A61K36/81 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61K47/44 ,  A61P1/02 ,  A61Q11/00

摘要： Compositions that include: from 5 wt-% to 30 wt-% of one or more plant based oils based on the total weight of the composition; from 70 wt-% to 95 wt-% of an aqueous phase based on the total weight of the composition; from 0.1 wt-% to 5 wt-% of one or more surfactants based on the total weight of the composition; and from 0.05 wt-% to 3 wt-% of a viscosity modifier, wherein the composition has a pH from 4.5 to 9.5, the composition is an oil in water (o/w) emulsion, and the composition is edible. Methods of utilizing disclosed compositions are also included.